Sight Diagnostics, Tel Aviv, Israel, the company behind the first FDA-cleared direct-from-fingerstick complete blood count analyzer, plans to use a new round of funding to expand its commercial operations in the United States and elsewhere, and to advance Sight’s research and development into the detection of additional diseases as well as biomarkers indicating covid-19 severity. “This new investment will enable Sight to substantially expand our US footprint and help usher in a new era of AI-driven diagnostics for a myriad of diseases and health conditions,” says Yossi Pollak, CEO and co-founder of Sight Diagnostics. “We’re glad to have Koch Disruptive Technologies, OurCrowd, and other esteemed investors join us on our mission to improve health systems and patient outcomes through developing fast, accurate, and less painful diagnostics.” Founded in 2011, Sight Diagnostics aims to transform blood testing through its flagship Sight Olo analyzer which automates the identification and quantification of different blood cell types and anomalies.  Since receiving FDA 510(k) clearance for Sight Olo in late 2019, Sight has continued to expand its global footprint with a specific focus on the US market. Thus far, Sight has secured contractual agreements with healthcare providers and distribution partners to deploy more than 1,000 analyzers over the coming years and will use the funds raised to meet this demand. Sight is also working with large pharmaceutical companies, including Pfizer, to provide support for different treatments and therapies. Since early in the pandemic, Sight has deployed its Sight Olo analyzer in frontline healthcare facilities outside of the United States fighting covid-19, including the globally renowned Sheba Medical Center at Tel Hashomer, Israel. In the United States, Sight Olo is 510(k) cleared for use in moderate complexity laboratories; it has not yet been cleared for point-of-care use. Outside of the United States, Sight Olo is CE Marked according to the IVD European directive and approved by the Australian TGA for point-of-care settings. For more information, visit Sight Diagnostics.